Affimed Therapeutics and Biopharma Unit of Syngenta Enter Into Agreement to Co-develop Tandabs
08-Nov-2004 -
Heidelberg. Affimed Therapeutics AG,
a Heidelberg, Germany-based drug development company, has signed a
partnership agreement with the biopharmaceutical unit of Syngenta AG of
Basel, Switzerland to co-develop one of Affimed's proprietary Tandab
antibodies.
Tandabs recruit the body's immune ...
antibody fragments
antigens
drug development
+1